REQUEST FOR THE PROPOSAL No. 03/2021-ARG – Development of formulation and manufacturing of investigational medicinal product – update of 23.02.2021
The order carried out as a part of the project titled:
– ARG: “PRE-CLINICAL AND CLINICAL DEVELOPMENT OF ARGINASE INHBITOR FOR CANCER IMMUNOTHERAPY” (POIR.01.01.01-00-0415/17)
co-financed by European Union Funds and because of the competitiveness principle.
We hereby look for Contractor ready to perform:
Development of formulation and manufacturing of investigational medicinal product (IMP) in accordance to Good Manufacturing Practice for clinical trials of phase I & II.
Załącznik_nr_5_Umowa o zachowaniu poufności_Appendix_no_5_CDA
On February 23, 2021, the Ordering Party has updated Appendix No. 5 in connection with the change of share capital. The deadline for submitting offers remains unchanged.
Załącznik_nr_5_Umowa o zachowaniu poufności_Appendix_no_5_CDA_aktualizacja 23.02.2021
In connection with the questions received to the request for quotation we provide answers to all uncertainties that have arisen before the deadline for submitting questions: